A pivotal strategic milestone for ImmuPharma was achieved through the receipt of a highly supportive Combined Search and Examination Report from the United Kingdom Intellectual Property Office concerning its P140 auto-immune patent filings. Building upon this positive regulatory evaluation, the company has progressed international …
The cornerstone of Chill Brands' operational repositioning centres on its proprietary Chill Connect distribution model. Under this revised framework, the company has deployed a dedicated field sales network servicing independent convenience retailers across the United Kingdom. Rather than relying solely on third-party wholesale brokers, …
The primary technological and commercial driver for Cambridge Nutritional Sciences (LSE:CNSL) is its proprietary Foodprint microarray platform. Designed to quantify food-specific immunoglobulin G (IgG) antibody reactions across extensive dietary panels, Foodprint enables accredited clinical laboratories and private healthcare clinics to process high-throughput diagnostic samples …
The operational focus of Coiled Therapeutics involves utilizing advanced cellular assays, high-throughput phenotypic screening, and computational structural biology to optimize lead chemical series. By collaborating with leading academic institutions and specialized specialist contract organisations (CROs), the company screens small-molecule compounds for biochemical potency, target …
The flagship commercial instrument within Creo's surgical suite is the Speedboat Inject, a specialised endoscopic device engineered for endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) of precancerous gastrointestinal lesions. By integrating tissue dissection, precise vessel coagulation, and needle-free liquid submucosal injection into …
The engine of ConvaTec's organic revenue growth is its accelerated R&D pipeline, highlighted by proprietary foam and antimicrobial dressing platforms. The company's flagship Aquacel Ag+ Extra dressings utilize patented Hydrofiber technology combined with ionic silver to manage wound exudate and disrupt pathogenic biofilms in …
The engine of Diaceutics' corporate growth is its proprietary DXRX platform, an end-to-end commercialisation platform that integrates laboratory diagnostic data from hundreds of clinical testing laboratories worldwide. Pharmaceutical companiesMarketingtargeted oncology, autoimmune, and rare disease therapeutics subscribe to DXRX to gain real-time visibility into diagnostic …
Recognising global regulatory shifts and consumer demands to curb veterinary antimicrobial usage in commercial farming, ECO Animal Health has aggressively pivoted R&D resources toward preventative biological vaccines. The group is developing novelVaccineplatforms targeting major livestock pathogens, including Mycoplasma hyopneumoniae in swine and avian respiratory …
The group's operational architecture is built upon two complementary commercial pillars: Core Point-of-Care Diagnostics and Life Sciences Contract Manufacturing. In point-of-care, EKF supplies proprietary analysers—including the Hemo-Control and DiaSpect haemoglobin meters—generating recurring, high-margin revenues from disposable microcuvettes and reagent strips. Simultaneously, its Life Sciences …
The core asset base of EMV Capital (LSE:EMVC) comprises shareholdings across innovative portfolio companies spanning point-of-care diagnostics, digital health, robotics, and clean technology. Key investee companies include PDS Biotechnology (targeted immunotherapies), ProAxsis (respiratory protease diagnostics), and robotic automation innovators. By actively participating on investee …